Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 4:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Primary Dyslipidemia Clear all
Completed Phase 2 Interventional

Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)

NCT01279590
View directory record Official record
Conditions
Myalgia, Hypercholesterolemia, Hyperlipidemia
Interventions
PPD10558, Atorvastatin, Placebo
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
40 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
67
States / cities
Anniston, Alabama • Phoenix, Arizona • Huntington Park, California + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2011 · Synced Sep 28, 2026, 4:58 PM EDT
Terminated Phase 3 Interventional

Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia

NCT00729027
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
25 mg/day AVE5530, 50 mg/day AVE5530, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,015 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 15, 2016 · Synced Sep 28, 2026, 4:58 PM EDT
Completed Not applicable Interventional Results available

The Medication Metronome Project - Study to Facilitate Follow-up Testing Resulting From Prescribed Medications to Improve Patient Safety and Care

NCT01586897
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypertension, Hyperlipidemia
Interventions
Medication Metronome, Usual Care
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 10, 2016 · Synced Sep 28, 2026, 4:58 PM EDT
Terminated Phase 3 Interventional Results available

CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases

NCT02697136
View directory record Official record
Conditions
Familial Hypoalphalipoproteinemia
Interventions
CER-001, Placebo
Drug
Lead sponsor
Cerenis Therapeutics, SA
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Sep 28, 2026, 4:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone

NCT00910988
View directory record Official record
Conditions
Hyperglycemia, Hyperlipidemia
Interventions
Olanzapine, Ziprasidone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 28, 2026, 4:58 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.

NCT05763875
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Inclisiran, Ezetimibe, Matching Placebo for Inclisiran, Matching Placebo for Ezetimibe
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
22
States / cities
Birmingham, Alabama • Dothan, Alabama • DeLand, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 28, 2026, 4:58 PM EDT
Completed Not applicable Interventional

Study of Medical Assistant Health Coaching in Primary Care for Patients With Chronic Conditions

NCT01220336
View directory record Official record
Conditions
Diabetes, Hypertension, Hyperlipidemia
Interventions
Health coaching by medical assistants in primary care
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Sep 28, 2026, 4:58 PM EDT
Completed Phase 3 Interventional

Efficacy of Lapaquistat Acetate Alone or Combined With Rosuvastatin in Subjects With Hypercholesterolemia

NCT00249912
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Lapaquistat acetate and rosuvastatin, Rosuvastatin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
82
States / cities
Birmingham, Alabama • Haleyville, Alabama • Mobile, Alabama + 79 more
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced Sep 28, 2026, 4:58 PM EDT
Completed Not applicable Interventional Results available

Coordinating Pragmatic Primary Care Population Management for Obesity

NCT03998046
View directory record Official record
Conditions
Obesity, Cardiovascular Risk Factor
Interventions
Outreach Support for Weight Loss Goal Setting and Self-Weighing, Outreach Decision Support to Encourage Linkages to Intensive Community Lifestyle Interventions, Adaptive Tailoring of Information Delivery and Intensity of Primary Care Outreach Support
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Sep 28, 2026, 4:58 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

NCT05739383
View directory record Official record
Conditions
Primary Prevention of Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Placebo in 1.5ml
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 79 Years
Enrollment
14,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
242
States / cities
Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 188 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 28, 2026, 4:58 PM EDT
Completed Phase 2 Interventional Results available

A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)

NCT04516291
View directory record Official record
Conditions
Dyslipidemias, Hyperlipidemias, Hyperlipoproteinemias
Interventions
Vupanorsen, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
59
States / cities
Gilbert, Arizona • Little Rock, Arkansas • Lincoln, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Sep 28, 2026, 4:58 PM EDT
Terminated Phase 3 Interventional

Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing High Doses of Statins in Patients With Primary Severe Hypercholesterolemia

NCT00766688
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
AVE5530, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 15, 2016 · Synced Sep 28, 2026, 4:58 PM EDT
Recruiting Not applicable Interventional

A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors

NCT07238556
View directory record Official record
Conditions
Hypertension, Dyslipidemia, Diabetes Mellitus, Obesity, Cardiovascular Disease
Interventions
Experimental - 12 Week P3-EX Unsupervised Exercise Program with Virtual Weekly Oversight from Graduate Research Assistants, Active Control - 12 Week ACSM-PAVS Unsupervised Exercise Program with Virtual Weekly Oversight from Graduate Research Assistants
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 64 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
3
States / cities
Farmington, Connecticut • Hartford, Connecticut • Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 28, 2026, 4:58 PM EDT
Completed Phase 3 Interventional Results available

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events

NCT01968967
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Bococizumab (PF-04950615; RN316), Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
155
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 115 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Sep 28, 2026, 4:58 PM EDT
Completed Not applicable Interventional Results available

Communicating Health Information and Improving Coordination With Primary Care

NCT03104543
View directory record Official record
Conditions
Hypertension, Dyslipidemias, Diabetes, Childhood Cancer
Interventions
Education, Test results only
Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Sep 28, 2026, 4:58 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Ezetimibe on the Absorption of Oxidized Cholesterol

NCT00794677
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
ezetimibe, placebo
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Sep 28, 2026, 4:58 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

NCT02023879
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Placebo (for Alirocumab), Non-statin LMT, Diet Alone
Drug · Other
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
8
States / cities
Beverly Hills, California • Atlantis, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Sep 28, 2026, 4:58 PM EDT
Terminated Not applicable Interventional

Pediatric Obesity Management Study

NCT05622981
View directory record Official record
Conditions
Obesity, Childhood, Behavior, Eating
Interventions
Age-specific educational materials and monitoring
Behavioral
Lead sponsor
Corewell Health East
Other
Eligibility
2 Years to 17 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 28, 2026, 4:58 PM EDT
Withdrawn Phase 2 Interventional

Study of MB07811 in Subjects With Hypercholesterolemia

NCT00879112
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
MB07811, Placebo
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
11
States / cities
San Diego, California • Jacksonville, Florida • Pembroke Pines, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2011 · Synced Sep 28, 2026, 4:58 PM EDT
Terminated Phase 3 Interventional

Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia

NCT00741715
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
AVE5530, atorvastatin, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 15, 2016 · Synced Sep 28, 2026, 4:58 PM EDT
Active, not recruiting Phase 4 Interventional

VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease

NCT06249165
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 28, 2026, 4:58 PM EDT
Completed Not applicable Interventional

Reducing Disparities in Primary Prevention of Cardiovascular Disease

NCT01610609
View directory record Official record
Conditions
Cardiovascular Diseases, Cholesterol, LDL
Interventions
Population Health Management Intervention
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
35 Years and older
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Flagstaff, Arizona • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 28, 2014 · Synced Sep 28, 2026, 4:58 PM EDT
Completed Phase 2 Interventional

Safety Study of BMS-823778 in Subjects With Hypercholesterolemia

NCT01112423
View directory record Official record
Conditions
Dyslipidemia
Interventions
BMS-823778, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
6
States / cities
Little Rock, Arkansas • Lenexa, Kansas • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Sep 28, 2026, 4:58 PM EDT
Completed Not applicable Interventional Results available

Cardiovascular Risk Screening and Risk Reduction in Women Vets

NCT02991534
View directory record Official record
Conditions
Cardiovascular Diseases, Hypertension, Hyperlipidemias, Dyslipidemias, Obesity, Diabetes Mellitus, Tobacco Use Disorder, Overweight
Interventions
CV Toolkit Components
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Female only
Enrollment
6,009 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Sepulveda, California • West Los Angeles, California • West Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Sep 28, 2026, 4:58 PM EDT